
Retina
Latest News
Latest Videos

Shorts








Podcasts
CME Content
More News

From treating myopic complications to preventing them, eye care providers have ample opportunity to close a collaborative care gap.

This week’s top stories include pipeline updates in dry eye, retinitis pigmentosa, contact lens hygiene, and more.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.

Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.

Sharon Fekrat, MD, FACS, FASRS, of Duke University, discusses how retinal imaging fits into the diagnostic picture for CVI, TBI, and neurodegenerative disease, and when eye care professionals should suspect a neurological cause.

EyeCon is an opportunity for ophthalmologists and optometrists to sit down together.

Mary Beth Yackey, OD, outlines all that you need to know about the role of oculomics in eye care.

Mogenry (sonpiretigene isteparvovec, MC-010) is a gene therapy for retinitis pigmentosa with severe vision loss.

Phase 3 Duravyu insert misses key vision end point in wet AMD but cuts injections; pivotal LUCIA readout may decide its future.

A maternal high-fat diet can negatively affect the retinal structure in mice.

Hamza Shah, OD, MS, FAAO, and Carolyn Majcher, OD, FAAO, weigh in on the recent FDA approval of the drug, which has been used off-label by compounding pharmacies for nearly 2 decades.

Catch up on the top stories in optometry during the week of August 3-7.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography–based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Physicians recommend a Mediterranean or similar diet to slow the progression of age-related macular degeneration, the leading cause of irreversible vision loss in older adults.

The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the US.

Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.

i-Lumen Scientific randomly assigned its first US patient in the sham-controlled i-SIGHT2 pivotal study of its investigational, noninvasive bioelectric AMD device at Texas Retina Associates.

Lab-grown retinal endothelial cells from iPSCs rebuild mouse retinal vessels and power blood-retina barrier chips, accelerating diabetic retinopathy research and therapy discovery.


























